1. Introduction {#sec1}
===============

Obstructive sleep apnea (OSA) is characterized by repetitive episodes of complete and/or partial interruption of the respiratory airflow during sleep, leading to oxygen desaturation and chronic intermittent hypoxia. OSA is highly prevalent in the general population, affecting at least 9--15% of middle-aged adults \[[@B1], [@B2]\]. OSA represents a growing healthcare problem, as it has been increasingly implicated in the causation or promotion of various cardiovascular diseases \[[@B3]\]. Earlier reports have demonstrated increases in pulmonary artery pressure (PAP) during sleep, which suggested the development of sustained pulmonary hypertension in patients with OSA \[[@B4], [@B5]\]. Indeed, studies have shown that daytime pulmonary hypertension occurs in 20% to 40% of patients with OSA and concomitant pulmonary or heart disease \[[@B6]--[@B8]\]. Moreover, permanent pulmonary hypertension may also develop in OSA patients in the absence of other known cardiopulmonary disorders \[[@B9], [@B10]\]. Although pulmonary hypertension in OSA is usually mild to moderate, it confers functional limitations and a poor prognosis \[[@B11]\]. Furthermore, pulmonary hypertension in OSA patients can lead to the development of right ventricular (RV) hypertrophy and dysfunction. However, radionuclide ventriculography studies have demonstrated that RV dysfunction may develop independently of pulmonary hypertension in these patients \[[@B12]\]. Importantly, alterations in RV structure and function have been shown to predict the clinical outcomes in cardiopulmonary diseases \[[@B13], [@B14]\].

Echocardiography is a noninvasive, low-cost, time-saving, and accurate tool for assessments of alterations in cardiac structure and function. Therefore, in clinical practice, ventricular structure and function are commonly assessed using echocardiography. In recent years, several echocardiographic studies have reported that OSA patients frequently present structural and functional alterations of the right ventricle \[[@B26]--[@B17], [@B22], [@B24], [@B25], [@B20], [@B18]--[@B21], [@B28]\]. However, since most of the studies were small and assessed few echocardiographic parameters, the outcomes from these studies have been inconsistent. Because large randomized controlled trials directly evaluating the impact of OSA on the structural and functional alterations of the right ventricle are lacking, we aimed to perform a systematic review of the literature and meta-analysis of studies based on the conventional echocardiographic assessment of RV structure and function in OSA patients.

2. Methods {#sec2}
==========

2.1. Search Strategy and Literature Screening {#sec2.1}
---------------------------------------------

A systematic literature review was conducted using electronic databases (PubMed, Web of Science, and Google Scholar). All databases were searched up to October 30, 2016, using the following terms: "obstructive sleep apnea", "sleep-disordered breathing", "right ventricular function", "right ventricular dysfunction", "right heart failure", and "echocardiography". In addition, we reviewed the reference lists from all relevant articles to find other potential sources. The process of selecting studies is outlined in [Figure 1](#fig1){ref-type="fig"}.

Articles were first screened by title and abstract, and reviews, guidelines, letters, case reports, editorials, and in vitro and animal studies were excluded. In a second screen, the following criteria were used to identify potentially suitable studies: (1) studies were written fully in English; (2) enrolled subjects were adults, above 18 years old; (3) OSA patients did not have major comorbidities; (4) the study included a control group; (5) OSA was diagnosed by polysomnography; (6) the study reported at least one of the measures of RV function and RV remodeling. After the abovementioned screening, the authors obtained the full-text articles and read them carefully and independently.

2.2. Data Extraction and Processing {#sec2.2}
-----------------------------------

Two independent reviewers (Abdirashit Maripov and Argen Mamazhakypov) screened and extracted data from full-text articles using standardized data extraction sheets. The following study characteristics were extracted from the articles: first author, publication year, country, numbers of patients and healthy controls, mean age, sample size, body mass index (BMI), mean apnea-hypopnea index (AHI), PAP values, and RV morphology and function parameters. The main echocardiographic parameters involved in the assessment of RV morphology and function were RV internal diameter (RVID), RV wall thickness (RVWT), RV fractional area change (FAC), RV myocardial performance index (MPI), pulsed-wave tissue Doppler imaging- (TDI-) derived velocity of the tricuspid annular systolic motion (RV S\'), and tricuspid annular plane systolic excursion (TAPSE). In cases of conflicting evaluations, disagreements were resolved through discussion between the authors.

2.3. Data Analysis {#sec2.3}
------------------

Several studies stratified patients based on OSA severity (mild, moderate, or severe) and reported grouped RV function data within each stratum. In those cases, because they represented independent samples, we considered each stratum as a separate substudy. All analyses were calculated using the statistical package Stata, version 14.1 (StataCorp, College Station, TX, USA) with the random-effects model. The weighted mean difference (WMD) with 95% confidence intervals (CIs) was calculated using a random-effects model. Fisher\'s *z* test was used to determine the statistical significance of the pooled WMDs. Cochran\'s *χ*^2^ test and the *I*^2^ statistic were used to assess between-study heterogeneity. Heterogeneity was considered statistically significant at *p* \< 0.10 and *I*^2^ \> 50%.

3. Results {#sec3}
==========

3.1. Literature Search {#sec3.1}
----------------------

Using electronic searches of the databases, 546 citations were obtained. We screened the studies through title and abstract review and removed duplicates, reviews, meta-analyses, nonhuman studies, case reports, and guidelines. Two hundred and five studies underwent full-text review. After full-text review, 180 studies were excluded according to the inclusion and exclusion criteria described above. A total of 25 studies with 1,503 OSA patients and 796 healthy control participants were included in this study. The flow diagram of the selection process is shown in [Figure 1](#fig1){ref-type="fig"}.

3.2. Characteristics of the Included Studies {#sec3.2}
--------------------------------------------

The publication years of the involved studies ranged from 1992 to 2016. The majority of the studies (12 studies, 48%) were conducted in Turkey; 4 studies were conducted in North America (USA and Canada), 3 studies were conducted in China, and 6 studies were conducted in Europe (Belgium, Germany, Poland, and Italy). In all studies, OSA was diagnosed by polysomnography. In the control groups, OSA was excluded based on polysomnography in 18 studies. In 7 studies, healthy control subjects were enrolled based on the absence of clinical symptoms of sleepiness \[[@B27], [@B16], [@B15], [@B32], [@B20], [@B18]\] or cardiovascular diseases \[[@B33]\]. For the assessment of RV remodeling, 16 studies (64%) used RVID and 9 studies (36%) used RVWT. For the assessment of RV function, 11 studies (44%) used TAPSE, 14 studies (56%) used RV MPI, 6 studies (24%) used RV FAC, and 14 studies (48%) used RV S\'. The main characteristics of the studies in this systematic review are listed in [Table 1](#tab1){ref-type="table"}.

3.3. Meta-Analysis {#sec3.3}
------------------

We performed a meta-analysis for changes in RV structure and function. Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"} show the changes in RVWT and RVID. Changes in RV MPI, RV S\', TAPSE, and RV FAC are shown in Figures [4](#fig4){ref-type="fig"}[](#fig5){ref-type="fig"}[](#fig6){ref-type="fig"}--[7](#fig7){ref-type="fig"}. [Table 2](#tab2){ref-type="table"} shows the summary data of all parameters of the RV structure and function determined by the meta-analysis. Heterogeneity was obvious in the assessment of the RV structure and function parameters, which could have been a result of differences in geographical location, participants\' ages, severities of disease, and RV remodeling.

### 3.3.1. RV Remodeling {#sec3.3.1}

To evaluate RV structure, RVID and RVWT were assessed. Changes in RVID were reported in 16 studies (22 strata) involving 902 OSA patients and 596 control subjects. The meta-analysis showed that the RVID in patients with OSA was significantly larger compared to the controls (WMD (95% CIs) 2.49 (1.62 to 3.37); *p* = 0.000; [Figure 2](#fig2){ref-type="fig"}). In addition, changes in RVWT were reported in 9 studies (16 strata) involving 579 patients with OSA and 379 control subjects. Patients with OSA had significantly increased RVWT compared to the controls (WMD (95% CIs) 0.82 (0.51 to 1.13); *p* = 0.000; [Figure 3](#fig3){ref-type="fig"}).

### 3.3.2. RV Function {#sec3.3.2}

To evaluate RV function, RV MPI, RV S\', TAPSE, and RV FAC were assessed. The most commonly reported RV functional parameters were RV MPI (14 studies, 26 strata, 864 patients with OSA and 434 control subjects) and RV S\' (14 studies, 23 strata, 639 patients with OSA and 391 control subjects). The TAPSE was reported in 11 studies (21 strata, 655 patients with OSA and 378 control subjects), while 6 studies assessed the RV FAC (15 strata, 422 patients with OSA and 239 control subjects). The meta-analysis demonstrated that the RV MPI was significantly elevated in patients with OSA compared to the controls (WMD (95% CI) 0.08 (0.06 to 0.10); *p* = 0.000; [Figure 4](#fig4){ref-type="fig"}). We also found significant differences between the patients with OSA and controls for RV S\' (WMD (95% CI) −0.95 (−1.59 to −0.32); *p* = 0.003; [Figure 5](#fig5){ref-type="fig"}). In addition, TAPSE (WMD (95% CI) −1.76 (−2.73 to −0.78); *p* = 0.000; [Figure 6](#fig6){ref-type="fig"}) and RV FAC (WMD (95% CI) −3.16 (−5.60 to −0.73); *p* = 0.011; [Figure 7](#fig7){ref-type="fig"}) were also significantly decreased in the patients with OSA compared to the controls.

4. Discussion {#sec4}
=============

To our knowledge, this is the first meta-analysis to systematically evaluate changes in RV structure and function in OSA patients. In this meta-analysis, 25 case-control studies were included, with a total of 1,503 patients with OSA and 796 healthy controls. In the present study, we found that alterations in echocardiographic parameters of RV remodeling, including an increase in RVWT and RVID, were important features in OSA patients without major comorbidities. Furthermore, our meta-analysis demonstrated that, in these patients, conventional echocardiography and pulsed-wave TDI-derived parameters of RV function were significantly altered compared to the controls. We found significant heterogeneity between studies. However, heterogeneity is to be expected given the variety of studies conducted by different teams at various geographic locations, the variation in disease severity, and differences in the patient populations. In most studies, the investigators were blinded to the participants\' study group status \[[@B36], [@B26], [@B17]--[@B34], [@B20], [@B18], [@B29]--[@B31], [@B28], [@B33]\]. In addition, interobserver agreement and intraobserver reproducibility were assessed in most of the studies \[[@B36], [@B26], [@B17], [@B22]--[@B32], [@B34], [@B20], [@B29], [@B21], [@B28], [@B33]\].

Although cardiac magnetic resonance imaging is considered as the gold standard for morphological and functional assessment of the right ventricle, conventional echocardiography remains the first-resort imaging modality in routine clinical practice due to its low cost, simplicity, reproducibility noninvasive nature, safety, and lack of ionizing radiation \[[@B37], [@B38]\]. However, accurate evaluation of RV morphology and function remains challenging in clinical practice due to its complex geometric shape \[[@B39]\]. Nevertheless, echocardiography was performed according to the recommendations of the American Society of Echocardiography in all of the studies included in the current meta-analysis \[[@B39]\].

Conventional echocardiography and pulsed-wave TDI allow for the assessment of RV function by quantifying RV FAC, MPI, TAPSE, and RV S\'. Several studies exploiting conventional echocardiography and tissue Doppler imaging have reported that OSA patients frequently present structural and functional alterations of the right ventricle \[[@B26]--[@B17], [@B22], [@B24], [@B25], [@B20], [@B18]--[@B21], [@B28]\]. In contrast, other studies did not reveal any changes in RV morphology and function in OSA patients by the application of conventional echocardiography and TDI \[[@B36], [@B35], [@B32], [@B34], [@B41], [@B40], [@B33]\]. Importantly, novel techniques, including 2D and 3D speckle-tracking echocardiography, are very sensitive and can reveal alterations in RV morphology and performance in early disease stages when changes in the conventional echocardiographic parameters are not yet present \[[@B32], [@B34], [@B21], [@B33]\]. However, these sophisticated techniques require expertise and have not been extensively validated for the assessment of RV function.

Multiple mechanisms underlie alterations in RV morphology and function in OSA patients \[[@B42]\]. Numerous studies have reported permanent pulmonary hypertension in OSA patients. In this population, pulmonary hypertension is often associated with chronic obstructive pulmonary disease \[[@B6], [@B7]\]. In addition, OSA patients with pulmonary hypertension often have cardiac comorbidities, including hypertension and left ventricular dysfunction. However, permanent pulmonary hypertension may also develop in OSA patients in the absence of other known cardiopulmonary disorders \[[@B9], [@B10]\]. Pulmonary hypertension in OSA patients can lead to the development of RV hypertrophy and dysfunction. Early studies have reported right heart failure in OSA patients that was associated with daytime hypoxemia due to underlying lung disease \[[@B43]\]. However, recent studies have demonstrated that RV function is impaired in OSA patients even after adjustments for potential confounders \[[@B12], [@B17], [@B34]\]. An independent effect of OSA on RV structure and performance was observed in a number of studies, showing a correlation between AHI and RV parameters, such as RV MPI \[[@B19], [@B17], [@B25]\], RV EF \[[@B12], [@B17]\], RV S\' \[[@B27], [@B16], [@B22]\], RVID \[[@B27]\], RVWT \[[@B25]\], TAPSE \[[@B25], [@B20]\], and RV strain variables \[[@B34], [@B20], [@B41]\]. Another possible mechanism that could lead to RV dysfunction in OSA patients is the generation of negative intrathoracic pressure against an occluded airway, causing increased venous return and volume overload of the right ventricle during apnea periods \[[@B20], [@B44]\]. During RV hypertrophy, myocardial oxygen demands may increase, leading to RV ischemia and dysfunction \[[@B42]\]. Additionally, OSA is much more common in obese individuals. It has been shown that isolated obesity in young adults is associated with subclinical abnormalities in RV structure and function, which are independent of the presence of OSA and its severity \[[@B45], [@B46]\].

5. Conclusions {#sec5}
==============

The present study represents the first systematic review of the literature and meta-analysis to explore RV involvement in OSA patients. We concluded that OSA patients display increased RV wall thickening and dilatation along with impaired RV function.
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![Forest plot of the differences in right ventricular internal diameter (RVID) at diastole between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.](CRJ2017-1587865.002){#fig2}

![Forest plot of the differences in right ventricular free wall thickness (RVWT) between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.](CRJ2017-1587865.003){#fig3}

![Forest plot of the differences in right ventricular myocardial performance index (RV MPI) between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.](CRJ2017-1587865.004){#fig4}

![Forest plot of the differences in right ventricular annular systolic velocity (RV S\') between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.](CRJ2017-1587865.005){#fig5}

![Forest plot of the differences in tricuspid annular plane systolic excursion (TAPSE) between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.](CRJ2017-1587865.006){#fig6}

![Forest plot of the differences in right ventricular fractional change (RV FAC) between the OSA patients and the healthy controls based on echocardiography. OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.](CRJ2017-1587865.007){#fig7}

###### 

Characteristics of the included studies. RVID: right ventricular basal diameter measured at end-diastole; RVWT: right ventricular wall thickness; RV MPI: right ventricular myocardial performance index; RV S\': tricuspid annular systolic velocity; TAPSE: tricuspid annular plane systolic excursion; RV FAC: right ventricular fractional area change; OSA: obstructive sleep apnea; ESS: Epworth Sleepiness Scale; PSG: polysomnography; AHI: apnea-hypopnea index; PAP: pulmonary artery pressure; N/A: not applicable.

  Study                             Year of publication                              Country                          Number of participants                                                Mean (SD) age (years)   BMI (kg/m^2^)     OSA diagnosis (methods; criteria)/control group determination   Mean (SD) ESS score   Mean (SD) AHI       Mean (SD) PAP (mmHg)   RV remodeling and dysfunction measures
  --------------------------------- ------------------------------------------------ -------------------------------- --------------------------------------------------------------------- ----------------------- ----------------- --------------------------------------------------------------- --------------------- ------------------- ---------------------- ----------------------------------------
  Hanly et al. \[[@B36]\]           1992                                             Canada                           31 (OSA)                                                              50 (12.3)               32.8 (7.2)        PSG; AHI \< 5 events/h                                          N/A                   49 (25.5)           N/A                    RVID, RVWT
  20 (control)                      48 (8.8)                                         26.2 (3.2)                       PSG; AHI ≥ 5 events/h                                                 N/A                     2.7 (1.6)         N/A                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                       
  Guidry et al. \[[@B26]\]          2001                                             USA                              90 (OSA)                                                              60 (9)                  32 (5)            PSG; RDI \> 90th percentile                                     N/A                   42.0 (15.3) (RDI)   N/A                    RV FAC, RVWT, RVID
  90 (control)                      61 (9)                                           28 (4)                           PSG; RDI \< 50th percentile                                           N/A                     4.6 (2.6) (RDI)   N/A                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                       
  Verbraecken et al. \[[@B27]\]     2005                                             Belgium                          43 (OSA)                                                              55 (11)                 31.6 (5.4)        PSG; AHI \> 20 events/h                                         N/A                   42 (24)             N/A                    RVID, RV MPI, RV S\'
  40 (control)                      50 (16)                                          26.4 (2.3)                       ESS score = 0 (all)                                                   N/A                     N/A               N/A                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                       
  Dursunoğlu et al. \[[@B19]\]      2005                                             Turkey                           11 (mild OSA)                                                         46.0 (5.6)              30.4 (4.0)        PSG; AHI \> 5--\< 15 events/h                                   N/A                   25.3 (2.6)          N/A                    RVWT, RVID, RV MPI
  18 (moderate-to-severe OSA)       46.5 (4.9)                                       30.6 (4)                         PSG; AHI ≥ 15 events/h                                                N/A                     50.1 (11.6)       N/A                                                                                                                              
  20 (control)                      43.5 (6)                                         29.3 (2.4)                       PSG; AHI \< 5 events/h                                                N/A                     5.2 (2.8)         N/A                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                       
  Shivalkar et al. \[[@B16]\]       2006                                             Belgium                          43 (OSA)                                                              55 (11)                 31.6 (5.4)        PSG; AHI ≥ 5 events/h                                           N/A                   N/A                 32 (10)                RVID, RV MPI, RV S\'
  40 (control)                      50 (16)                                          26.4 (2.3)                       ESS score = 0 (all)                                                   N/A                     N/A               22 (8)                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                       
  Kasikcioglu et al. \[[@B15]\]     2007                                             Turkey                           10 (OSA)                                                              42 (6)                  30.6 (3.2)        PSG: AHI \> 30 events/h                                         N/A                   43.8 (11.7)         N/A                    RVID, RV S\'
  10 (control)                      45 (9)                                           27.7 (2.6)                       Healthy males                                                         N/A                     2.1 (1.0)         N/A                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                       
  Romero-Corral et al. \[[@B17]\]   2007                                             USA                              15 (mild OSA).                                                        59 (14)                 33 (6)            PSG; AHI \> 5--\< 14 events/h                                   N/A                   9.2 (2.9)           33.6 (12.7)            RV MPI, RV FAC
  36 (moderate-to-severe OSA)       63 (14)                                          33 (5)                           PSG; AHI ≥ 15 events/h                                                N/A                     34.9 (17.9)       33.9 (8.4)                                                                                                                       
  26 (control)                      55 (15)                                          31 (6)                           PSG; AHI \< 5 events/h                                                N/A                     1.7 (1.4)         34.0 (9.4)                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                       
  Otto et al. \[[@B35]\]            2007                                             USA                              23 (OSA)                                                              45 (3)                  33.7 (0.8)        PSG; AHI ≥ 5 events/h                                           N/A                   50 (7)              N/A                    RVID, RV S\'
  18 (control)                      45 (2)                                           32.3 (0.9)                       PSG; AHI \< 5 events/h                                                N/A                     2 (0.4)           N/A                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                       
  Tavil et al. \[[@B22]\]           2007                                             Turkey                           20 (OSA)                                                              50 (7)                  30 (7)            PSG; AHI ≥ 5 events/h                                           N/A                   31 (29)             N/A                    TAPSE, RV S\', RV MPI
  21 (control)                      49 (5)                                           29 (6)                           PSG; AHI \< 5 events/h                                                N/A                     2 (2)             N/A                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                       
  Bayram et al. \[[@B24]\]          2008                                             Turkey                           28 (OSA)                                                              44.8 (10.5)             29.7 (5.3)        PSG; AHI ≥ 15 events/h                                          N/A                   62.3 (21.6)         N/A                    RVID, RV S\',
  18 (control)                      41.9 (11.5)                                      27.9 (2.7)                       PSG; AHI \< 5 events/h                                                N/A                     2.6 (0.8)         N/A                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                       
  Kepez et al. \[[@B32]\]           2009                                             Turkey                           45 (mild-to-moderate OSA)                                             48.8 (8.2)              28.4 (3.4)        PSG; AHI \> 5--\< 30 events/h                                   N/A                   15.0 (13.0)         N/A                    RVID, RV S\'
  40 (severe OSA)                   48.6 (9.2)                                       31.5 (4.9)                       PSG; AHI ≥ 30 events/h                                                N/A                     46.0 (42.0)       N/A                                                                                                                              
  30 (control)                      46.1 (8.7)                                       27.7 (4.0)                       Absence of symptoms of sleep-related disorders                        N/A                     N/A               N/A                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                       
  Tugcu et al. \[[@B25]\]           2009                                             Turkey                           41 (OSA)                                                              56 (12)                 31.38 (4.97)      PSG; AHI ≥ 15 events/h, ESS score ≥ 10                          19.37 (4.30)          38.84 (21.80)       28.20 (4.66)           RVWT, TAPSE, RV MPI, RV S\'
  30 (control)                      54 (10)                                          30.10 (3.65)                     PSG; AHI \< 5 events/h, ESS score \< 10                               2.60 (2.29)             1.46 (0.68)       24.73 (2.49)                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                       
  Tugcu et al. \[[@B34]\]           2010                                             Turkey                           27 (OSA)                                                              54 (10)                 31.1 (5.1)        PSG; AHI ≥ 15 events/h, ESS score ≥ 10                          N/A                   40 (22)             26.6 (3.1)             RVWT, RVID, TAPSE, RV S\'
  26 (control)                      54 (10)                                          29.6 (3.6)                       PSG; AHI \< 5 events/h, ESS score \< 10                               N/A                     2 (1)             24.1 (2.3)                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                       
  Yang et al. \[[@B47]\]            2012                                             China                            77 (mild OSA)                                                         58.4 (0.7)              27.39 (5.74)      PSG; AHI 5--15 events/h, SpO~2~ nadir 85--89%                   N/A                   20 (5.6)            28 (6)                 RVID, RVWT, RV MPI,
  81 (moderate OSA)                 PSG; AHI 15--30 events/h, SpO~2~ nadir 80--84%   N/A                              38 (6)                                                                                                                                                                                                                                           
  62 (severe OSA)                   PSG; AHI \> 30 events/h, SpO~2~ nadir \<80%      N/A                              55 (11)                                                                                                                                                                                                                                          
  75 (control)                      59.8 (1.1)                                       26.32 (4.57)                     PSG; AHI \< 5 events/h                                                N/A                     2.9 (2)           22 (5)                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                       
  Altekin et al. \[[@B20]\]         2012                                             Turkey                           20 (mild OSA)                                                         46.95 (6.4)             28.68 (3.44)      PSG; AHI \> 5--\< 15 events/h                                   N/A                   10.73 (2.57)        27.62 (4.32)           RV MPI, TAPSE
  19 (moderate OSA)                 46.79 (5)                                        29.05 (2.26)                     PSG; AHI \> 15--\< 30 events/h                                        N/A                     20.52 (2.60)      29.78 (4.24)                                                                                                                     
  19 (severe OSA)                   46.68 (7.6)                                      29.80 (2.38)                     PSG; AHI ≥ 30 events/h                                                N/A                     58.1 (16.27)      32.06 (3.71)                                                                                                                     
  21 (control)                      45.38 (4.5)                                      26.35 (4.14)                     ESS score \< 10                                                       N/A                     N/A               25.61 (5.43)                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                       
  Hammerstingl et al. \[[@B41]\]    2012                                             Germany                          154 (OSA)                                                             61.7 (12.4)             31.1 (5.8)        PSG; AHI \< 5 events/h                                          10.4 (5.2)            35.9 (28.4)         22.0 (12.6)            TAPSE, RV MPI
  29 (control)                      55.7 (15.8)                                      30.1 (5.5)                       PSG; AHI ≥ 5 events/h                                                 7.9 (5.6)               2.3 (1.3)         17.3 (11.9)                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                       
  Öztuna et al. \[[@B18]\]          2013                                             Turkey                           23 (OSA)                                                              53.6 (7.1)              34.8 (7.8)        PSG; AHI ≥ 15 events/h                                          9.17 (5.10)           N/A                 21.8 (5.9)             RV MPI
  23 (control)                      53.7 (6.5)                                       25.8 (1.7)                       ESS score \< 10                                                       0.26 (0.54)             N/A               22.1 (4.4)                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                       
  Araz et al. \[[@B30]\]            2014                                             Turkey                           67 (OSA)                                                              49.7 (12.7)             34.6 (8.3)        PSG; AHI ≥ 5 events/h                                           10 (4)                52 (6)              41.2 (12.9)            RVID
  31 (control)                      49.8 (10.9)                                      29.5 (7.3)                       PSG; AHI \< 5 events/h                                                3 (2)                   1.5 (1.4)         25.3 (7.5)                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                       
  Vitarelli et al. \[[@B29]\]       2015                                             Italy                            10 (mild OSA)                                                         47.9 (10.3)             26.9 (5.8)        PSG; AHI \> 5--\< 15 events/h                                   N/A                   7.1 (1.9)           25 (6)                 TAPSE, RV MPI, RV FAC, RV S\'
  8 (moderate OSA)                  47.6 (9.1)                                       27.4 (5.5)                       PSG; AHI \> 15--\< 30 events/h                                        N/A                     19.8 (2.7)        35 (11)                                                                                                                          
  19 (severe OSA)                   48.1 (10.2)                                      28.2 (6.3)                       PSG; AHI ≥ 30 events/h                                                N/A                     58.9 (9.1)        46 (11)                                                                                                                          
  30 (control)                      46.2 (13.4)                                      26.4 (4.3)                       PSG; AHI \< 5 events/h                                                N/A                     3.8 (1.4)         22 (3)                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                       
  Ozkececi et al. \[[@B23]\]        2016                                             Turkey                           30 (OSA)                                                              49.6 (11.7)             31.6 (5.8)        PSG;AHI ≥ 5 events/h                                            N/A                   24.5 (6--98)        22.4 (8.9)             RVID, RV MPI, RV S\', TAPSE
  60 (control)                      46.4 (14)                                        29.3 (4.8)                       PSG; AHI \< 5 events/h                                                N/A                     1 (1--4)          12.7 (7.5)                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                       
  Altiparmak et al. \[[@B31]\]      2016                                             Turkey                           52 (OSA)                                                              49 (10)                 26.5 (2.1)        PSG; AHI ≥ 5 events/h                                           N/A                   N/A                 32.4 (7)               RVID, RVWT, TAPSE, RV S\'
  42 (control)                      46(7)                                            25.8(3.3)                        PSG; AHI \< 5 events/h                                                N/A                     N/A               21.6 (4.3)                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                       
  Li et al. \[[@B21]\]              2016                                             China                            24 (mild OSA)                                                         47.3 (6.1)              26.40 (3.12)      PSG; AHI \> 5--\< 15 events/h                                   N/A                   12.72 (2.03)        N/A                    RVWT, RVID, TAPSE, RV FAC
  25 (moderate OSA)                 47.9 (7.9)                                       26.83 (3.55)                     PSG; AHI \> 15--\< 30 events/h                                        N/A                     24.01 (3.56)      N/A                                                                                                                              
  20 (severe OSA)                   48.5 (5.4)                                       27.97 (3.59)                     PSG; AHI ≥ 30 events/h                                                N/A                     40.78 (5.02)      N/A                                                                                                                              
  31 (control)                      46.8 (5.4)                                       24.86 (2.78)                     PSG; AHI \< 5 events/h                                                N/A                     1.72 (1.01)       N/A                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                       
  Dobrowolski et al. \[[@B40]\]     2016                                             Poland                           45 (mild OSA)                                                         47.5 (10.5) All         N/A               PSG; AHI \> 5--\< 15 events/h                                   N/A                   N/A                 N/A                    TAPSE, RV FAC, RV S\'
  27 (moderate OSA)                 N/A                                              PSG; AHI \> 15--\< 30 events/h   N/A                                                                   N/A                     N/A                                                                                                                                                
  40 (severe OSA)                   N/A                                              PSG; AHI ≥ 30 events/h           N/A                                                                   N/A                     N/A                                                                                                                                                
  43 (control)                      N/A                                              PSG; AHI \< 5 events/h           N/A                                                                   N/A                     N/A                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                       
  Zhou et al. \[[@B28]\]            2016                                             China                            21 (mild OSA)                                                         52.8 (11.9)             29.6 (9.1)        PSG; AHI \> 5--\< 15 events/h                                   N/A                   N/A                 35.7 (6.1)             RV FAC, RV MPI
  19 (moderate OSA)                 55.7 (12.4)                                      35.2 (10.1)                      PSG; AHI \> 15--\< 30 events/h                                        N/A                     N/A               33.4 (5.8)                                                                                                                       
  23 (severe OSA)                   50.2 (12.1)                                      39.2 (9.8)                       PSG; AHI ≥ 30 events/h                                                N/A                     N/A               18.7 (6.9)                                                                                                                       
  19 (control)                      52.0 (10.8)                                      24.2 (3.7)                       PSG; AHI \< 5 events/h                                                N/A                     N/A               16.7 (6.2)                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                       
  D\'Andrea et al. \[[@B33]\]       2016                                             Italy                            55 (OSA)                                                              67.8 (11.2)             33.6 (6.6)        PSG; AHI ≥ 5 events/h                                           N/A                   35.1 (15.4)         35.8 (14.4)            RVID, RVWT, TAPSE
  45 (control)                      65.9 (12.3)                                      28.7 (3.6)                       Absence of cardiovascular, structural, and functional abnormalities   N/A                     N/A               24.8 (11.3)                                                                                                                      

###### 

Results of the meta-analysis comparing OSA patients and healthy controls. RVID: right ventricular basal diameter measured at end-diastole; RVWT: right ventricular wall thickness; RV MPI: right ventricular myocardial performance index; RV S\': tricuspid annular systolic velocity; TAPSE: tricuspid annular plane systolic excursion; RV FAC: right ventricular fractional area change; OSA: obstructive sleep apnea; WMD: weighted mean difference; CI: confidence interval.

  Echocardiographic parameters   Number of studies   OSA/control   WMD (95% CI)           *p* value   Study heterogeneity   Egger\'s test *p* value           
  ------------------------------ ------------------- ------------- ---------------------- ----------- --------------------- ------------------------- ------- -------
  RVID                           16                  902/596       2.49 (1.62, 3.37)      0.000       96.8%                 647.61                    0.000   0.001
  RVWT                           9                   579/397       0.82 (0.51, 1.13)      0.000       95.6%                 344.56                    0.000   0.671
  RV MPI                         14                  864/434       0.08 (0.06, 0.10)      0.000       84.1%                 157.39                    0.000   0.150
  RV S\'                         14                  639/391       −0.95 (−1.59, −0.32)   0.003       88.4%                 190.21                    0.000   0.347
  TAPSE                          11                  655/378       −1.76 (−2.73, −0.78)   0.000       89.3%                 187.24                    0.000   0.462
  RV FAC                         6                   422/239       −3.16 (−5.60, −0.73)   0.011       80.2%                 70.83                     0.000   0.006

[^1]: Academic Editor: R. Andrew Mcivor
